Targeted Oncology4d
High-Grade Toxicity Rates Influence Choice of IO in Melanoma
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...
Le Lézard5d
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II ...